Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2022-04-10 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
第三届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 12th meeting of the 3rd Board of Directors of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting's attendance, agenda items, voting results, and decisions made, including termination of capital increase agreements and stock issuance plans. The content focuses on board decisions and management-level corporate governance matters rather than financial results, audit opinions, or shareholder voting outcomes. It is not a full annual or interim report, nor a call transcript or earnings release. The document is a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is 1922 characters, which is consistent with a meeting resolution announcement rather than a full report.
2022-04-10 Chinese
第三届监事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution by Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda, and voting results regarding the termination of a specific share issuance plan. The content focuses on board-level decisions and governance matters rather than financial results, audit opinions, or shareholder voting outcomes. It is not a full annual or interim report, nor an earnings release or capital update. The document is a formal disclosure of board/management decisions, specifically about terminating a capital increase plan via private placement. Therefore, it fits best under Board/Management Information (MANG). The document length is short and does not contain financial statements or detailed financial data, so it is not a report publication announcement or regulatory filing. Confidence is high due to clear governance content and meeting resolution format.
2022-04-10 Chinese
2021年年度报告说明会预告公告
Investor Presentation Classification · 95% confidence The document is a notice announcing a scheduled annual report earnings explanation meeting (业绩说明会) for the 2021 annual report of Jiangsu Deyuan Pharmaceutical Co., Ltd. It references the 2021 annual report published earlier (公告编号：2022-047) and invites investors to participate in a webcast meeting to discuss the annual report results. The document does not contain the annual report itself or detailed financial data, but rather announces the meeting to explain the annual report. The document length is short (967 characters) and it is clearly an announcement of a meeting related to the annual report, not the report itself. According to the classification rules, such announcements of report explanation meetings fall under Investor Presentation (IP) as they focus on financials, strategy, and market position presented to investors.
2022-04-07 Chinese
关于2021年内部控制自我评价报告的公告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制自我评价报告的公告" which translates to "Internal Control Self-Evaluation Report Announcement" for the year 2021. It contains detailed information about the company's internal control evaluation, including principles, scope, procedures, and conclusions about the effectiveness of internal controls over financial and non-financial reporting. The document is comprehensive and includes substantive content about internal control systems, risk assessments, control activities, and audit oversight. It is not merely an announcement of a report but the report itself, given the length (over 13,000 characters) and detailed content. The document does not fit categories like Annual Report (10-K), Earnings Release, or Management Reports specifically, but it aligns with the definition of an Audit Report / Information (AR) as it is a standalone report on internal control evaluation and related audit information. Therefore, the appropriate classification is AR with high confidence. FY 2021
2022-03-29 Chinese
2021年年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as the "2021 Annual Independent Directors' Report" from Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the independent directors' attendance at board and shareholder meetings, their independent opinions on various company matters, and their supervisory activities during the 2021 fiscal year. The content focuses on governance, compliance with laws and regulations, and the independent directors' duties and evaluations. It does not contain financial statements or detailed financial performance data, nor is it a presentation or announcement of voting results. The document is a report by independent directors on their activities and oversight, which fits best under Board/Management Information (MANG) as it relates to board members' roles and responsibilities rather than a full annual report or audit report. The document length is 3733 characters, which is relatively short but contains substantive content about board activities rather than just an announcement. Therefore, the classification is MANG with high confidence.
2022-03-29 Chinese
监事会关于回购注销2021年限制性股票激励计划部分限制性股票的意见
Transaction in Own Shares Classification · 95% confidence The document is a formal announcement from the supervisory board of Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the repurchase and cancellation of restricted shares under the 2021 restricted stock incentive plan. It references regulatory rules related to stock repurchase and employee stock plans, and details the approval and compliance of the repurchase action. The document is short (781 characters) and focuses on a specific transaction involving the company's own shares (repurchase and cancellation of restricted stock). It does not contain financial statements or broader financial performance data. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers company buybacks or cancellations of its own shares.
2022-03-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.